Program
Methoxsalen
Also written as “methoxsalen”, “ECP Methoxsalen” and “Methoxsalen +ECP”.
Its studies are mostly in Graft vs Host Disease · Colitis · Melanoma · Bronchiolitis Obliterans Syndrome · Crohn Disease, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keenova Therapeutics | 50 open or running | phase 2since Feb 5, 2003 | Feb 5, 2003 | none ahead |
| Therakos | 21 open or running | phase 2since Oct 15, 2024 | Oct 15, 2024 | Dec 2028phase 2 · NCT07619898 |
| Therakos | 10 open or running | no phasesince Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Therakos, Inc., a Mallinckrodt | 10 open or running | phase 3since Aug 13, 2015 | Aug 13, 2015 | none ahead |
Also a collaborator on its studies: parexel and icon-plc.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 1999First study: no phase study in HIV InfectionsNew to TherakosTherakos · NCT00002011 · United States
- Feb 5, 2003Keenova Therapeutics's first studies: 2 phase 2 studies in Graft vs Host DiseaseNew to Keenova TherapeuticsKeenova Therapeutics · NCT00054613, NCT00054600
- Sep 13, 20052 phase 2 studiesKeenova Therapeutics · NCT00221026, NCT00221000
- Jun 22, 2011Early phase 1 study in Bronchiolitis Obliterans SyndromeKeenova Therapeutics · NCT01380535 · 60 enrolled · United States, Austria, France and more
- Aug 13, 2015Therakos, Inc., a Mallinckrodt's first study: phase 3 study in Steroid Refractory Acute Graft Versus Host DiseaseNew to Therakos, Inc., a MallinckrodtTherakos, Inc., a Mallinckrodt · NCT02524847 · 29 enrolled · United States, Austria, France and more
- Oct 15, 2024Therakos's first study: phase 2 study in MelanomaNew to TherakosTherakos · NCT06646016 · United States
- May 19, 2026Phase 2 study in ColitisTherakos · NCT07619898 · 112 planned
Ahead
- Dec 2028Primary completion: phase 2 study in ColitisTherakos · NCT07619898
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07619898Colitis | 2 | Not yet recruiting | Therakos | Dec 2028 | 112 |
| NCT06646016Melanoma · United States | 2 | Withdrawn | Therakos | Feb 6, 2026 | 0 |
| NCT02524847Steroid Refractory Acute Graft Versus Host Disease · United States, Austria, France and more | 3 | Terminated | Therakos, Inc., a Mallinckrodt | Jul 16, 2019 | 29 |
| NCT01380535Bronchiolitis Obliterans Syndrome · United States, Austria, France and more | Early 1 | Completed | Keenova Therapeutics | Mar 2015 | 60 |
| NCT00221026Crohn Disease · United States, Austria, Belgium and more | 2 | Completed | Keenova Therapeutics | Jun 2006 | 25 |
| NCT00221000Arthritis, Rheumatoid · United States, Australia, Austria and more | 2 | Completed | Keenova Therapeutics | Oct 2006 | 86 |
| NCT00054613Graft vs Host Disease · United States, Australia, Austria and more | 2 | Completed | Keenova Therapeutics | 72 | |
| NCT00054600Graft vs Host Disease · United States, Australia, Brazil and more | 2 | Completed | Keenova Therapeutics | 60 | |
| NCT00002011HIV Infections · United States | – | Completed | Therakos |
How it is read
Names in the registry
- “Methoxsalen”, 6 entries
- “methoxsalen”, 1 entry
- “ECP Methoxsalen”, 1 entry
- “Methoxsalen +ECP”, 1 entry
Conditions, from the studies’ own filings
- Graft vs Host Disease, 3 studies
- Colitis, 1 study
- Melanoma, 1 study
- Bronchiolitis Obliterans Syndrome, 1 study
- Crohn Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.